Chemo Combo May Be a Bladder Cancer Treatment Alternative During BCG Shortage
Elisa Becze, BA, ELS, Editor
Voice
Description
Overall survival among patients with non–muscle-invasive bladder cancer who are treated with adjuvant gemcitabine and docetaxel is comparable to overall survival for treatment with bacillus Calmette-Guérin (BCG), researchers reported in the Journal of Urology. The evidence could support a treatment alternative for high-risk patients during the BCG shortage.